CompletedPhase 1NCT01431664

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cancer Research UK
Principal Investigator
Josef Vormoor
Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Intervention
multikinase inhibitor AT9283(drug)
Enrollment
7 enrolled
Eligibility
18 years · All sexes
Timeline
20112014

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01431664 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials